These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 24219051)

  • 1. Mapping utilities from cancer-specific health-related quality of life instruments: a review of the literature.
    McTaggart-Cowan H; Teckle P; Peacock S
    Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):753-65. PubMed ID: 24219051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preferences for health outcomes and cost-utility analysis.
    Torrance GW
    Am J Manag Care; 1997 May; 3 Suppl():S8-20. PubMed ID: 10180342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping between 6 Multiattribute Utility Instruments.
    Chen G; Khan MA; Iezzi A; Ratcliffe J; Richardson J
    Med Decis Making; 2016 Feb; 36(2):160-75. PubMed ID: 25840901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Taking quality of life into account in health economic analyses.
    Weeks J
    J Natl Cancer Inst Monogr; 1996; (20):23-7. PubMed ID: 8750463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should "standard gamble" and "'time trade off" utility measurement be used more in mental health research?
    Flood C
    J Ment Health Policy Econ; 2010 Jun; 13(2):65-72. PubMed ID: 20919593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
    Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
    J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elicitation of informed general population health state utility values: a review of the literature.
    McTaggart-Cowan H
    Value Health; 2011 Dec; 14(8):1153-7. PubMed ID: 22152187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen for breast cancer risk reduction: impact of alternative approaches to quality-of-life adjustment on cost-effectiveness analysis.
    Melnikow J; Birch S; Slee C; McCarthy TJ; Helms LJ; Kuppermann M
    Med Care; 2008 Sep; 46(9):946-53. PubMed ID: 18725849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health-state utility values in breast cancer.
    Peasgood T; Ward SE; Brazier J
    Expert Rev Pharmacoecon Outcomes Res; 2010 Oct; 10(5):553-66. PubMed ID: 20950071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of multiple sclerosis condition-specific measures to inform health policy decision-making: mapping from the MSWS-12 to the EQ-5D.
    Hawton A; Green C; Telford CJ; Wright DE; Zajicek JP
    Mult Scler; 2012 Jun; 18(6):853-61. PubMed ID: 22108867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health outcomes in economic evaluation: the QALY and utilities.
    Whitehead SJ; Ali S
    Br Med Bull; 2010; 96():5-21. PubMed ID: 21037243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valuing health for clinical and economic decisions: directions relevant for rheumatologists.
    Harrison MJ; Bansback NJ; Marra CA; Drummond M; Tugwell PS; Boonen A
    J Rheumatol; 2011 Aug; 38(8):1770-5. PubMed ID: 21807800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality of life, satisfaction, and economic outcome measures in studies of prostate cancer screening and treatment, 1990-2000.
    McNaughton-Collins M; Walker-Corkery E; Barry MJ
    J Natl Cancer Inst Monogr; 2004; (33):78-101. PubMed ID: 15504921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What affects the quality of economic analysis for life-saving investments?
    Hahn RW; Kosec K; Neumann PJ; Wallsten S
    Risk Anal; 2006 Jun; 26(3):641-55. PubMed ID: 16834624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Economic evaluation of targeted cancer therapy].
    Ikeda S
    Gan To Kagaku Ryoho; 2013 Aug; 40(8):967-70. PubMed ID: 23986036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does adjusting for health-related quality of life matter in economic evaluations of cancer-related interventions?
    Greenberg D; Neumann PJ
    Expert Rev Pharmacoecon Outcomes Res; 2011 Feb; 11(1):113-9. PubMed ID: 21351863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using whole disease modeling to inform resource allocation decisions: economic evaluation of a clinical guideline for colorectal cancer using a single model.
    Tappenden P; Chilcott J; Brennan A; Squires H; Glynne-Jones R; Tappenden J
    Value Health; 2013 Jun; 16(4):542-53. PubMed ID: 23796288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between quality of life instruments, health state utilities, and willingness to pay in patients with asthma.
    Blumenschein K; Johannesson M
    Ann Allergy Asthma Immunol; 1998 Feb; 80(2):189-94. PubMed ID: 9494453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preference-based measures in economic evaluation in health care.
    Neumann PJ; Goldie SJ; Weinstein MC
    Annu Rev Public Health; 2000; 21():587-611. PubMed ID: 10884966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.